Ionis Pharmaceuticals IONS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's stock-based comp?
- Ionis Pharmaceuticals (IONS) reported stock-based comp of $4.82M in Q4 2025.
- How has Ionis Pharmaceuticals's stock-based comp changed year-over-year?
- Ionis Pharmaceuticals's stock-based comp increased by 79.5% year-over-year, from $2.68M to $4.82M.
- What is the long-term trend for Ionis Pharmaceuticals's stock-based comp?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's stock-based comp has grown at a -0.7% compound annual growth rate (CAGR), from $19.55M to $19.27M.
- What does stock-based comp mean?
- The tax cost associated with share-based compensation that cannot be deducted from taxable income.
- How do you interpret stock-based comp?
- Higher values indicate a larger portion of equity compensation is non-deductible, potentially increasing the effective tax rate.
- How does stock-based comp compare across companies?
- Common reconciliation item for companies with significant stock-based compensation programs.